Concurrently, the study evaluating i.c.m. injection of AAVhu68-GLB1 in infant and juvenile GM1 gangliosidosis patients is ongoing, with outcomes yet to be disclosed (NCT04713475). This evidence concerns the gene GLB1 and GM1 gangliosidosis.